These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 18089334)

  • 1. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation.
    Pescovitz MD; Jain A; Robson R; Mulgaonkar S; Freeman R; Bouw MR
    Transplant Proc; 2007 Dec; 39(10):3111-6. PubMed ID: 18089334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
    Brown F; Banken L; Saywell K; Arum I
    Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.
    Winston DJ; Baden LR; Gabriel DA; Emmanouilides C; Shaw LM; Lange WR; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):635-40. PubMed ID: 16737936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
    Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
    Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of valganciclovir in pediatric transplant recipients.
    Launay E; Théôret Y; Litalien C; Duval M; Alvarez F; Lapeyraque AL; Phan V; Larocque D; Poirier N; Lamarre V; Ovetchkine P
    Pediatr Infect Dis J; 2012 Apr; 31(4):405-7. PubMed ID: 22198827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
    Kiser TH; Fish DN; Zamora MR
    J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
    Pescovitz MD; Pruett TL; Gonwa T; Brook B; McGory R; Wicker K; Griffy K; Robinson CA; Jung D
    Transplantation; 1998 Oct; 66(8):1104-7. PubMed ID: 9808499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.
    Vezina HE; Brundage RC; Balfour HH
    Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.
    Tängdén T; Cojutti PG; Roberts JA; Pea F
    Clin Pharmacokinet; 2018 Nov; 57(11):1399-1405. PubMed ID: 29546589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients.
    Zhao W; Fakhoury M; Fila M; Baudouin V; Deschênes G; Jacqz-Aigrain E
    Ther Drug Monit; 2012 Jun; 34(3):326-30. PubMed ID: 22495424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.
    Vaudry W; Ettenger R; Jara P; Varela-Fascinetto G; Bouw MR; Ives J; Walker R;
    Am J Transplant; 2009 Mar; 9(3):636-43. PubMed ID: 19260840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.
    Carmichael RJ; Whitfield C; Maxwell LK
    J Vet Pharmacol Ther; 2013 Oct; 36(5):441-9. PubMed ID: 23301502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
    Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients.
    Zhao W; Baudouin V; Zhang D; Deschênes G; Le Guellec C; Jacqz-Aigrain E
    Clin Pharmacokinet; 2009; 48(5):321-8. PubMed ID: 19566115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
    Jung D; Dorr A
    J Clin Pharmacol; 1999 Aug; 39(8):800-4. PubMed ID: 10434231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.